JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

15.25 4.88

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.37

Максимум

15.29

Ключови измерители

By Trading Economics

Приходи

-14M

-25M

Продажби

-5.5M

66M

Марж на печалбата

-38.059

Служители

342

EBITDA

-14M

-19M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+45.49% upside

Дивиденти

By Dow Jones

Следващи печалби

6.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-33M

1.8B

Предишно отваряне

10.37

Предишно затваряне

15.25

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.08.2025 г., 23:11 ч. UTC

Печалби

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5.08.2025 г., 22:45 ч. UTC

Печалби

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5.08.2025 г., 22:39 ч. UTC

Печалби

Great-West Lifeco Logs Lower 2Q Profit

5.08.2025 г., 21:32 ч. UTC

Печалби

Coupang Posts Higher 2Q Sales Due to Customer Growth

6.08.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6.08.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6.08.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6.08.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5.08.2025 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5.08.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5.08.2025 г., 23:19 ч. UTC

Пазарно говорене

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5.08.2025 г., 23:03 ч. UTC

Пазарно говорене
Печалби

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5.08.2025 г., 22:22 ч. UTC

Печалби

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5.08.2025 г., 22:21 ч. UTC

Печалби

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5.08.2025 г., 22:20 ч. UTC

Печалби

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5.08.2025 г., 22:18 ч. UTC

Печалби

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5.08.2025 г., 22:17 ч. UTC

Печалби

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5.08.2025 г., 22:17 ч. UTC

Печалби

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5.08.2025 г., 22:16 ч. UTC

Печалби

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5.08.2025 г., 22:16 ч. UTC

Печалби

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5.08.2025 г., 22:15 ч. UTC

Печалби

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5.08.2025 г., 22:13 ч. UTC

Печалби

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5.08.2025 г., 22:13 ч. UTC

Печалби

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5.08.2025 г., 22:12 ч. UTC

Печалби

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5.08.2025 г., 22:12 ч. UTC

Печалби

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5.08.2025 г., 21:58 ч. UTC

Печалби

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5.08.2025 г., 21:30 ч. UTC

Печалби

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5.08.2025 г., 21:26 ч. UTC

Печалби

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5.08.2025 г., 21:23 ч. UTC

Печалби

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5.08.2025 г., 21:17 ч. UTC

Печалби

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

45.49% нагоре

12-месечна прогноза

Среден 20.79 USD  45.49%

Висок 29 USD

Нисък 14.29 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

7

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.